The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.

Petros Christopoulos, Klaus Kluck, Martina Kirchner, Heike Lüders, Julia Roeper, Roger-Fei Falkenstern-Ge, Marlen Szewczyk, Florian Sticht, Felix C Saalfeld, Claas Wesseler, Björn Hackanson, Sebastian Dintner, Martin Faehling, Jonas Kuon, Melanie Janning, Diego Kauffmann-Guerrero, Daniel Kazdal, Sylke Kurz, Florian Eichhorn, Farastuk BozorgmehrRajiv Shah, Amanda Tufman, Martin Wermke, Sonja Loges, Wolfgang M Brueckl (Co-author), Christian Schulz, Daniel Misch, Nikolaj Frost, Jens Kollmeier, Martin Reck, Frank Griesinger, Christian Grohé, Jin-Liern Hong, Huamao M Lin, Jan Budczies, Albrecht Stenzinger, Michael Thomas

Research output: Contribution to journalOriginal Article (Journal)peer-review

17 Citations (Web of Science)
Original languageEnglish
Pages (from-to)106-118
JournalEUROPEAN JOURNAL OF CANCER
Volume170
DOIs
Publication statusPublished - 2022

Keywords

  • PRETREATED PATIENTS
  • MOBOCERTINIB
  • NSCLC
  • SURVIVAL
  • DIAGNOSIS

Cite this